Myelodysplastic syndrome (MDS)
Conditions
Interventions
Sponsors
University Medical Centre NIjmegen
Departmetn of Hematology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with MDS according to WHO 2001-criteria (RA, RARS, RAEB-1, RAEB-2, RCMD, RCMD-RS, MDS with isolated del(5q), MDS-U); 2. Patient with IPSS low-risk, intermediate-1 or intermediate-2 risk; 3. Untreated patients or patients treated with blood transfusions, growth factors, iron chelation therapy, the immunomodulatory drug lenalidomide or the hypomethylating agents azacitidine or decitabine; 4. Informed consent and of legal age at the time of obtaining informed consent (≥18yrs).
Exclusion criteria
Exclusion criteria: 1. Patients with previous intensive anti-leukemic therapy (intensive chemotherapy and/or stem cell transplantation); 2. Patients with secondary or therapy-related AML and MDS after chemotherapy for a malignancy or radiotherapy; 3. Patients with IPSS high risk MDS; 4. Patients with a contraindication for MRI: Gadolinium allergy, impaired kidney function (MDRD <45 mL/min/1.73m2), metal parts, internal defibrillator, pacemaker, neurostimulator, bladder stimulator, insulin pump, cochlear implant, claustrophobia or another reason that prohibits MRI evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A relationship between T2*Liver and or T2*Heart levels and the number of blood transfusions. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evidence for iron overload in transfusion-independent and transfusion-dependent MDS patients due to ineffective erythropoiesis. | — |
Contacts
Public ContactM. MacKenzie
University Medical Centre Nijmegen Geert Grooteplein z8
Outcome results
None listed